PGxHealth to Present Data on Replication of Genetic Associations with Clozapine-Induced Agranulocytosis at International Congress on Schizophrenia Research.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) announced today that its PGxHealth[TM] division, provider of Therapeutic Diagnostics[TM], will present data on the confirmation of a genetic marker associated with clozapine-induced agranulocytosis (CIA) at the International Congress on Schizophrenia Research (ICOSR) to be held March 28 through April 1, 2007, in Colorado Springs, CO. CIA is a rare but serious side effect of clozapine, an antipsychotic indicated for treatment-resistant schizophrenia.

At the conference, PGxHealth will detail results of a case-control study that confirmed findings from an earlier candidate gene-based case-control study. These data will be presented in a poster session to be held Friday, March 30. Both the initial study and the replication analysis evaluated the significance of genetic associations with risk of developing CIA. Positive results from the first study, presented at ICOSR in 2005, identified genetic variations associated with susceptibility to CIA. These latest data will describe the replication of a genetic association with risk for CIA in a second, independent cohort of patients.

PGxHealth's PGxPredict[TM]:CLOZAPINE test, launched in early 2007, is based on this research. This is a pharmacogenetic test that classifies patients as being at "Lower Risk" or "Higher Risk" for developing CIA compared to the general (untested) population. The PGxPredict:CLOZAPINE test is intended for practitioner use as an adjunct to existing clinical information to aid in determining the risk of developing CIA and better assessing the risk-benefit ratio of treatment with clozapine.

Separately, the Company notes that it will participate in the upcoming meeting of the Society of Biological Psychiatry, to be held May 17-19, 2007, where the PGxHealth team will further discuss their research. In addition, the PGxHealth team will also participate at the American Psychiatric Association annual meeting, May 19-24, 2007, where they will promote the PGxPredict:CLOZAPINE test at Exhibitor Booth #2214. Both meetings will be held in San Diego.

"The PGxPredict:CLOZAPINE test is a prime example of the value that pharmacogenetics can bring to patient safety, leveraging genetic variation to better understand each individual's probability of an adverse drug response, before prescribing a drug," said Carol R. Reed, MD, Clinical Data's Senior Vice President and Chief Medical Officer. "Despite evidence from the CATIE (Clinical Antipsychotic Trials for Interventions Effectiveness) study that clozapine is one of the most effective antipsychotics for the treatment-refractory schizophrenia population, clozapine today captures only 7% of the antipsychotic market. Its under-utilization is directly driven by CIA, a serious -- though rare -- side effect of clozapine. Clozapine's efficacy paired with its lower cost as a generic compared to branded antipsychotics makes it an optimal treatment choice. We feel that we can add to its value with PGxPredict:CLOZAPINE."

About Schizophrenia

Schizophrenia is a chronic mental health condition affecting 1% of the US population. The hallmark symptoms of schizophrenia include hallucinations, delusions, and disordered thought processes. This chronic disorder leads to a high degree of disability, and antipsychotic drugs are necessary to manage the condition and prevent relapse. Intolerable side effects are a common cause of treatment failure and noncompliance.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide.

About PGxHealth

PGxHealth[TM] has extensive experience and capabilities in the development, clinical validation and delivery of genomic-based tests, in particular in the areas of efficacy and safety biomarkers for appropriate drug utilization. Through its own know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers Therapeutic Diagnostics[TM].

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our PGxPredict tests will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Internet Website: www.clda.com